Zelatriazin (NBI-1065846 or TAK-041) is a small-molecule agonist of GPR139. It was developed for schizophrenia and anhedonia in depression, but trials were unsuccessful and its development was discontinued in 2023.

See also List of investigational antidepressants List of investigational antipsychotics List of investigational cognition and memory disorder drugs

References